Epstein–Barr virus-targeted therapy in nasopharyngeal carcinoma

Despite successful primary treatment of nasopharyngeal carcinoma (NPC), the incidence of distant metastasis remains 25–34 %. Treatment options are limited, and survival is poor. Intratumoural Epstein–Barr virus (EBV) was used as treatment target. In NPC, EBV is present in a latent state, expressing only few non-immunogenic viral products. Gemcitabine and… CONTINUE READING